Eurofins Discovery, has renewed its collaboration with Italy-based Dompé Farmaceutici for a second year. The partnership aims to leverage Eurofins Discovery’s comprehensive Integrated Drug Discovery capabilities alongside Dompé’s cutting-edge AI platform to accelerate the identification of new therapeutics.
The renewed collaboration builds on the success of combining Eurofins Discovery’s DiscoveryOne™ platfor, specializing in optimized screening cascades, automated chemical synthesis, and high-quality data generation, with Dompé’s supercomputing-powered AI platform, Exscalate. This partnership demonstrates how Eurofins Discovery can support companies using advanced AI technologies in their drug discovery efforts.
Eurofins Discovery brings extensive expertise to the table, with a vast portfolio of more than 12,000 assays and specialized experience in protein production, high-throughput screening, biophysics, ADME, pharmacokinetics, and synthetic chemistry. Their integrated drug discovery capabilities are essential to the collaboration’s success, enabling the efficient design and execution of multi-target projects.
Dompé Farmaceutici, known for its innovative approach to drug discovery, contributes the Exscalate AI platform, one of the most powerful supercomputing systems in the world. This platform can evaluate trillions of molecules for each novel target, greatly speeding up the process of identifying potential therapeutics. Eurofins Discovery’s expertise complements Dompé’s AI-driven virtual screening, making it an ideal partner to advance research aimed at improving human health.
With Eurofins Discovery’s support, Dompé is able to maximize the potential of its AI platform, and the collaboration is expected to yield important advances in drug discovery in the coming year.